🔬 Ivermectin and Cancer: What the Research Actually Shows

By Sam, Founder of FarmFitUSA · Researched and written in-house · Last reviewed August 2026

A straight answer to the question, including what the laboratory studies genuinely found, why that has not translated to people, and what would have to happen before it did.

A straight answer to the question, including what the laboratory studies genuinely found, why that has not translated to people, and what would have to happen before it did.

The Short Answer First

There is no clinical evidence that ivermectin treats cancer in humans. No randomised controlled trial has demonstrated that it shrinks tumours, extends survival or improves any patient-relevant outcome. It is not approved for cancer by any regulator, and no major oncology body recommends it.

There is genuine preclinical research — laboratory and animal studies — showing antitumour activity through several mechanisms. That research is real, it is published in peer-reviewed journals, and it is why the question keeps coming up.

Both statements are true simultaneously. Most pages on this subject give you one and hide the other. This one gives you both, and explains the gap between them, because the gap is the entire story.

What the Preclinical Research Actually Found

Since roughly 2010 a body of work has examined ivermectin in cancer cell lines and animal models. The proposed mechanisms include:

WNT/β-catenin pathway inhibition. This pathway is dysregulated in colorectal and other cancers. Ivermectin has been reported to suppress it in cell lines.

PAK1 inhibition. PAK1 is involved in proliferation and survival signalling in several tumour types.

Mitochondrial disruption. Reported interference with mitochondrial biogenesis and oxidative phosphorylation in leukaemia cells, increasing reactive oxygen species.

SIN3A/SID interaction, explored in breast cancer models.

Reversal of multidrug resistance. Ivermectin interacts with P-glycoprotein, the efflux pump that expels chemotherapy drugs from resistant tumour cells. In theory, inhibiting it could make existing chemotherapy work better — this is one of the more mechanistically interesting proposals.

Immunogenic cell death, reported in some models, potentially relevant to combining with immunotherapy.

This is a legitimate body of work. Researchers are not fabricating it, and the people asking about it are not being unreasonable.

Why It Has Not Translated

Here is the part that gets left out.

The concentration problem. This is the central issue. The antitumour effects in these studies typically appear at concentrations substantially higher than the plasma levels achievable in humans at approved doses. The therapeutic dose for parasites produces low plasma concentrations, sustained briefly. Reaching and holding the concentrations used in cell culture would require dosing associated with neurotoxicity.

This is exactly the same problem that sank the antiviral hypothesis, and it is not a technicality — it is the difference between a molecule doing something in a dish and a drug doing something in a person.

A dish is not a body. Cell culture lacks blood supply, immune system, metabolism, protein binding and tumour architecture. The great majority of compounds showing antitumour activity in vitro fail in humans. This is the normal outcome of drug development, not a conspiracy.

Mouse models are not people. Xenograft models — human tumours grown in immunodeficient mice — routinely show responses that do not reproduce in patients. Oncology has decades of experience with this.

Human trials are essentially absent. There are early-phase studies exploring ivermectin in combination settings. There is no phase III data. Without it, there is no basis for a clinical claim.

Why This Matters More Here Than Elsewhere

With most supplements, being wrong costs money. In oncology, being wrong costs years of life.

Delayed treatment is the harm. Many cancers are curable when treated early and become incurable when they are not. A person who postpones surgery, chemotherapy or radiotherapy for months to try ivermectin may pass the point where cure was possible. This is documented across alternative cancer treatments generally, with measurably worse survival in patients who choose them over conventional treatment first.

Financial harm is real. People spend heavily on protocols with no evidence.

False hope has its own cost. Being told something will work, and watching it not work, is not a neutral experience for a patient or a family.

None of that means the research should stop. It means the difference between "under investigation" and "works" has to be stated honestly, because a patient making a decision needs to know which one they are looking at.

If You Are Considering It

Tell your oncologist. This is the single most useful thing on this page. Not because they will necessarily object, but because ivermectin interacts with P-glycoprotein, which handles many chemotherapy drugs. That interaction is precisely why it was investigated — and it means it can plausibly alter the levels of drugs you are actually relying on. Concealing it is genuinely dangerous.

Do not substitute it for treatment. Adding something is a different decision from replacing something.

Look for a clinical trial instead. If you want to access investigational treatments, trials give you monitoring, dose-finding and data collection. ClinicalTrials.gov lists what is recruiting.

Be sceptical of protocols sold to you. Anyone charging for a cancer protocol built on preclinical data is selling certainty that does not exist.

Watch for the veterinary formulation problem. Covered in Ivermectin: What It Actually Is — animal products are concentrated for animals weighing hundreds of kilograms.

What Would Change This

A specific, answerable question: adequately powered randomised controlled trials in humans showing improved survival or tumour response, at doses achievable without unacceptable toxicity.

If those trials are run and are positive, the answer here changes and this guide gets rewritten. That is how it should work. Until then, the honest position is that this is a hypothesis with laboratory support and no clinical evidence.

The Bottom Line

Ivermectin is an outstanding antiparasitic drug with a Nobel Prize and a genuine legacy. Its documented human uses — covered in Ivermectin for Skin and Ivermectin for Intestinal Parasites — are real and underappreciated.

The cancer research is interesting and preliminary. It does not currently support treating cancer with ivermectin, and treating a curable cancer with it instead of established therapy is a decision that can cost a life.

REFERENCES

• Published preclinical studies of ivermectin in cancer cell lines and animal models, including work on WNT/β-catenin, PAK1 and mitochondrial mechanisms.
• FDA prescribing information for ivermectin (Stromectol); no oncology indication is approved.
• National Cancer Institute information on evaluating complementary and alternative cancer therapies.
• Published research on survival outcomes among patients who use alternative therapies in place of conventional cancer treatment.
• ClinicalTrials.gov, for current registered studies.

Common Questions

Does ivermectin cure cancer?

No. There is no clinical evidence in humans that it treats cancer, and no regulator has approved it for that use. There is preclinical laboratory and animal research showing antitumour activity, which is not the same thing.

Why do the lab studies look so promising?

Because effects in cell culture are common and rarely translate. In this case the effects typically require concentrations far above what a human can safely achieve, which is the central obstacle.

Is there any human trial data?

Some early-phase exploratory work exists. There is no phase III evidence, which is what a clinical claim would require.

Can I take it alongside chemotherapy?

Only with your oncologist's knowledge. Ivermectin interacts with P-glycoprotein, which handles many chemotherapy drugs, so it can plausibly alter the levels of the treatment you are relying on.

What is the actual harm in trying?

Delay. Many cancers are curable early and incurable later, and patients who use alternative therapies in place of conventional treatment have measurably worse survival. Adding something is a different decision from replacing something.

Educational and informational purposes only. FarmFitUSA content is not medical or veterinary advice and is not intended to diagnose, treat, remedy, or prevent any disease. These statements have not been evaluated by the FDA. Consult a qualified professional before acting on anything here, and call a vet or a doctor when the situation warrants it.